<SEC-DOCUMENT>0001213900-25-100129.txt : 20251020
<SEC-HEADER>0001213900-25-100129.hdr.sgml : 20251020
<ACCEPTANCE-DATETIME>20251020065825
ACCESSION NUMBER:		0001213900-25-100129
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20251020
FILED AS OF DATE:		20251020
DATE AS OF CHANGE:		20251020

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		251402288

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0261762-6k_immuron.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Month of October 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: 001-38104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>IMMURON LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMURON LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron Limited (the &ldquo;Company&rdquo;) published
an announcement (the &ldquo;Public Notice&rdquo;) to the Australian Securities Exchange on October 20, 2025 titled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in">- &nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Emerging Growth Conference</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B> <BR>
<B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea026176201ex99-1_immuron.htm">Emerging Growth Conference</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 62%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 20, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea026176201ex99-1_immuron.htm
<DESCRIPTION>EMERGING GROWTH CONFERENCE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immuron
CEO, Steven Lydeamore to present at Emerging Growth Conference</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Melbourne, Australia, October 20, 2025: Immuron
Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the
Emerging Growth Conference on Wednesday 22<SUP>nd</SUP> October 2025 (4:10pm - 4:20pm U.S. Eastern Time).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Steven Lydeamore, Chief Executive Officer
will perform a presentation and may subsequently open the floor for questions. Please submit your questions in advance to Questions@EmergingGrowth.com
or ask your questions during the event. Mr. Lydeamore will do his best to get through as many of them as possible.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please register to ensure you are able to attend this conference and
receive any updates that are released.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">https://goto.webcasts.com/starthere.jsp?ei=1717092&amp;tp_key=1ddfafa563&amp;sti=imrn</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If attendees are not able to join the event live
on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube
channel, <FONT STYLE="font-size: 10pt">http://www.YouTube.com/EmergingGrowthConference</FONT><FONT STYLE="font-size: 10pt">.
</FONT>A link will be released after the event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release has been authorised by the directors
of Immuron Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - END - - -</P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><B>COMPANY CONTACT:</B> <B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Steven Lydeamore</B> <BR>
Chief Executive
Officer<BR>
 steve@immuron.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>About Immuron</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Immuron Limited (ASX:
IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal
antibodies for the treatment of infectious diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Travelan<SUP>&reg;</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Travelan<SUP>&reg;</SUP>
is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers&rsquo; diarrhea,
<FONT STYLE="background-color: white">a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce</FONT>.
Travelan<SUP>&reg;</SUP> is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when
taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers&rsquo; diarrhea.
In Australia, Travelan<SUP>&reg;</SUP> is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated
to reduce the risk of Travelers&rsquo; Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan<SUP>&reg;</SUP> is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers&rsquo;
Diarrhea. In the U.S., Travelan<SUP>&reg;</SUP> is sold as a dietary supplement for digestive tract protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: #FEFEFE"><B><IMG SRC="ex99-1_002.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: #FEFEFE"><B><IMG SRC="ex99-1_003.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>Travelers&rsquo;
diarrhea (TD)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">TD is generally defined
as the passage of &ge; 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps,
fever, blood/mucus in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any resource-limited
destinations (Leung et al., 2006). Diarrhea continues to be the most
frequent health problem among travelers to destinations in lower- and middle-income regions (Steffen,
2017). Deployed US military personnel, essentially representing a long-term traveller population, are particularly affected given
their population dynamics and the context in which they seek care and treatment (Connor
et al., 2012). Diarrhea is the leading infectious disease threat to the overall health and preparedness of deployed US armed forces,
with diarrheagenic E. coli, Campylobacter spp., and Shigella spp. among the most commonly reported etiologies (Riddle
et al., 2006).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Immuron Platform Technology</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Immuron&rsquo;s proprietary
technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability
of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the
acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine
IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found
there. The underlying nature of Immuron&rsquo;s platform technology enables the development of medicines across a large range of infectious
diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize
the toxins they produce.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>IMM-124E (Travelan<SUP>&reg;</SUP>)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B><SUP>&nbsp;</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">IMM-124E was developed
using Immuron&rsquo;s platform technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised during
pregnancy with a vaccine containing the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in the vaccine
to produce high levels of antibodies against selected surface antigens from the most common strains of ETEC. (Otto
et al., 2011)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">The resultant hyperimmune
colostrum IMM-124E from ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for ETEC antigens LPS, CFA-I
and Flagellin (Sears et al., 2017).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">The antibodies produced
in IMM-124E have been found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated cattle) against
a wide range of LPS antigens including both the variable O-polysaccharide region and the preserved oligosaccharide core &lsquo;R&rsquo;
region of LPS from the 13 serotypes used in the ETEC vaccine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">IMM-124E is manufactured
into a tablet form referred to as Travelan<SUP>&reg;</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>IMM-529</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Immuron is developing IMM-529 as an adjunctive
therapy in combination with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection
(CDI). IMM-529 antibodies targeting Clostridioides difficile (C. diff) may help to clear CDI infection and promote a quicker re-establishment
of normal gut flora, providing an attractive oral preventative for recurrent CDI.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Immuron is collaborating with Dr. Dena Lyras
and her team at Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised
to generate hyperimmune bovine colostrum (HBC) that contains antibodies targeting three essential C. diff virulence components. IMM-529
targets Toxin B (TcB), the spores and the surface layer proteins of the vegetative cells.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">This unique 3-target approach has yielded
promising results in pre-clinical infection and relapse models, including (1) Prevention of primary disease (80% P =0.0052); (2) Protection
of disease recurrence (67%, P &lt;0.01) and (3) Treatment of primary disease (78.6%, P&lt;0.0001; TcB HBC). Importantly IMM-529 antibodies
cross-react with whole cell lysates of many different human strains of C. diff including hypervirulent strains.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">To our knowledge, IMM-529 is, to date, the
only investigational drug that has shown therapeutic potential in all three phases of the disease (Hutton
et al., 2017).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><IMG SRC="ex99-1_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><IMG SRC="ex99-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>ProIBS<SUP>&reg;</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Immuron has an exclusive
distribution agreement with Calmino goup AB for the territories of Australia and New Zealand for ProIBS<SUP>&reg;</SUP>. ProIBS<SUP>&reg;</SUP>
- to help patients treat IBS symptoms ProIBS<SUP>&reg;</SUP> is a certified medical device for the treatment of IBS symptoms such as
abdominal pain, bloating and unsettled bowel movements (diarrhoea and/or constipation). ProIBS<SUP>&reg;</SUP> contains AVH200<SUP>&reg;</SUP>,
derived from the plant Aloe barbadensis. Mill. AVH200<SUP>&reg;</SUP> has gel forming components which support the intestinal mucosal
barrier. As IBS is known to affect individuals for a long period of time, it is essential to have a treatment appropriate for long-term
use &ndash;as ProIBS<SUP>&reg;</SUP> is. The product is safe, and no interactions with other medications are known. Science-driven innovative
Calmino group AB, the developer of ProIBS<SUP>&reg;</SUP>, conducted a usability study among 1,003 users. PROIBS<SUP>&reg;</SUP> was
helpful for 94% of them. 91% of the users experienced an improvement in daily life and 98% would recommend PROIBS<SUP>&reg;</SUP> to
someone else. To learn more please check: www.proibs.eu.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Irritable bowel syndrome (IBS) is a common
condition where you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits
and stress levels or mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected. Some key symptoms
of IBS include: abdominal pain or discomfort; stomach bloating and wind; chronic diarrhoea or constipation, or alternating between the
two.(healthdirect.gov.au) According to available data, the
IBS treatment market in Australia is estimated to be a part of the broader &ldquo;Digestives &amp; Intestinal Remedies&rdquo; market, generating
a revenue of around AU$221.14 million in 2025, with a projected annual growth rate of 3.28%.(Statista)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>References</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Connor P, Porter CK,
Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5):
546-54; 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Hutton, M.L., Cunningham,
B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative.
Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Leung AK, Robson WL,
Davies HD. Travelers&rsquo; diarrhea. Adv Ther. Jul-Aug; 23(4): 519-27; 2006</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Otto W, Najnigier B,
Stelmasiak T and Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea
caused by enterotoxigenic Escherichia coli in volunteers Scandinavian Journal of Gastroenterology 46: 862&ndash; 868; 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Riddle MS, Sanders
JW, Putnam SD, and Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers&rsquo; (US military and similar populations):
A systematic review. American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Sears KT, Tennant SM,
Reymann MK, Simon R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic
Escherichia coli Hyperimmune Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Steffen R. Epidemiology
of travelers&rsquo; diarrhea. J Travel Med. 24(suppl_1): S2-S5; 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">For more information
visit: https://www.immuron.com.au/ and https://www.travelan.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Subscribe to Immuron&rsquo;s
InvestorHub: Here</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FORWARD-LOOKING STATEMENTS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management&rsquo;s current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock
value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !* 0P# 2(  A$! Q$!_\0
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M\;W^D64\MS9Z;>>)M L-7N;&UN)E2::WMIKMX89)5$CQHI<;B:_D!_X. ?\
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MRTZ\81_BM_X. ?\ D^S1_P#LAO@'_P!/WC2OZM_V(?\ DSC]EO\ [(%\*/\
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M^I:$X_1OQZU]CX,I+Q!\2_+ 9^E_XD69?Y(^/\97?@#PV[/'9#?_ ,1[+?\
M-G]]%AC[#98X'V2VP/0>2E?GI_P5FLXKW_@GM^TI',BNL/A'3+Q0P!Q+9>*-
M"NHG&0<,DD2NIZ@@'(K]"[#_ (\;+_KTMO\ T2E? 7_!5;_E'Y^TW_V(:?\
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M1P590P('T5=Z7IE^R/?:=87KQJ51[NTM[ED4D,51IHW*J6 ) (!(!(R*N@
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M9C65#F]O6==IY@XNHU33]DFH+G:C^8G_  6)TS5]5_X)\_'"WT;3KW4YXO\
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MU\(/#-[H>I^,(KO:G]CWUTU_KFOW=M<E2DFFZ;>VL%[&SV]U!<P/)&_Z1_\
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MC3HN%7+9TIS7MG";J1E",Z4H&C2$ @@@$$$$$9!!X((/!!'45Y3X+^.GP?\
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MFHRW5U9ZG'I*6[V\-]+?6"1WUO;R+^&ES^WZG@-M)_9:_P""Q?['ND_%_4/
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M+ 7GL[BS*W<5W&&MWM/])63R1OK^RWPG^VM^R;X[TGQKKW@WX_\ PS\2:/\
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MB:>,I4J-&C['"P6)KXIJ&+HXK$T\6G.O*$9PY(J,4VG.Z11117YP?HH4444
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MP=^T5\6_"MA<S?ZZYLO#_@71])M;B;))\V:&T263D@,Y PH '>_LW?$/1O\
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MS49N"RRKF%'#1IPAC:G-4I4\14K*4]%%%?G9^A!1110 4444 %%%% !1110
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !4 S$# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLUM=VTR26FH:?>16^H:;?07%AJ%K;7MO/!'_  U?MH_ _P#9T^,WPX3]KO\
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MM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BL'7?%7ACPO ;KQ+XCT'P[; 9-QKNL:?I,  Y),U_<6\8 '.=V
M*^=_%/[;G[)G@[SAK'Q[^'D[VY(FA\/:Q_PE\Z, 3M,/A*'6Y=V!TV]>#@U[
M&6</<09W)0R;(<[S>3=DLKRC-,P5_P#%@\OQ%-?]O58GAYMQ/PSD$'//>(^'
M\EA%7;S?/,HRQI;WY,=F>%JO_MVC._2Y]345^7?BW_@KO^R-X>CF.BW?C_QQ
M*FX1+H'A2/3HI74<!F\6ZIX<N8D8\!_LCGD$(1S7S%XP_P""W&AQ;HO GP-N
M[P$L$OO%/C)+,HNWY7?2M+T&Z$A#<-&FM(".1*,<_I.4^ /C%G'*\/P'G&%I
MSM:KF\L!DM-)_:E_:684JR2O=_[+S+^6^A^4YS])7P,R/G6*\1LCQE2'->CD
MD,QSZJW'[,7E665J#;M9?[9RO^>VI^\-%?R_>+O^"R'[2^MO-'X;TCX<>#;9
M@5ADT[P]>:EJ47/#R3^(M7UJPE<#CC2XD[[*^6_%W_!0']KGQHMQ'JWQS\9V
MD5P7W1^&[RW\'*D;DDPH/"%KH0,8!V_.'8J "Q&<_IF4_0_\2\;R2S7-.$\C
M@[.49YAC<WKP[KV>5X"G1;MT^MVOIS=3\ESKZ<7A/@.>.3Y/QIQ#.-U"5/+,
M!DF'GOK[7.,RJ5U&]M7@[VU4>A_8QJ&IZ;I-L]YJNH6.F6<8)DNM0NX+*VC
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M(_Q+R/$T<%G648S$.V'PN9X#$5W9RY:-+%T9U)\J3;]G&]6R3;]C:*<G%/\
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M<?4XZ]L"O\S)?1/\6UM2X6G_ (>):*_]*RN)_K''Z9G@M+XJO&,/\7"E9_\
MI&<2/[0J*_C-3_@X1_;/7[_@;]GU^<_\B=XW7CTX^)/Z]:NQ_P#!PQ^V&H^?
MX<_L^2')Y_X17QZN0>GW?B6!Q_\ KSUK)_13\7EMA.&GZ<3X-?\ I67HV7TQ
M_!)[XWBR/KPCCG_Z3F;/[):*_CB7_@X<_:\ PWPO_9[<\_,?#7Q!&?3@?$T#
MBI4_X.'_ -K@'Y_A7^STP]/^$<^(8_E\3JA_15\8/^A?PX_3BG+_ -<$B_\
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M[\U'_:NJ 8&HWR@]0MW.H/U"R ?A7IT?H98)6^L>(6,EW^K\,X2'W/$9S/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  R +<# 2(  A$! Q$!_\0
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M^$?"VG6%M#9V-AX<T.RLK.WC6*WM;2UTRU@MK:") $CA@AC2**- %1%55
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M';S/ 8;_ %:#3[E8C;ZOJNCZGH6K:E^H9( ))P!R2>@'J:_)KXJV_P +9O\
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M%_ L>KG4=(L9X(9?%O'_ ,3?^"Z/[$>GP?&+XK:SJGC_ .'-BT-SXIAU3_A
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MP+33%;4M*^$7PXGULVVM>,]>U/5FCOO$VN/;VL6IWMII<DZ6>@>&4U:?TO\
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6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
